Pharmacology (Working group III)

Scientific context and objective

Group leader: S. Pastorekova

Lead drugs, including drugs under development by European companies, which antagonize oxygen-dependent protein hydroxylation (Epo replacement, metabolic tissue protection, pre-conditioning, therapeutic angiogenesis) or HIF function (cancer treatment, inflammatory suppression), will be studied for their in vitro and in vivo functions by the members of the COST Action.

Aim

Aim is to develop and investigate drugs that are able to modulate the hypoxia signalling pathways.

Members registered: 13

| Register

After succesfull login you will by able to manage your participation in groups or our posts in forum.

Forgot password?
Login or go back to page

Forgotten password

If you have forgotten your password, have no worries. Just type in your email address and we'll send you a new one.

Send me new password or go

| Register

After registering you gain acces to joining Working gropus or to post Forum question or answers. You can choose if you want to be member or just a regular participant.

i.e. within 10 years after finishing their Doctoral degree
text
Finish registration or go back to page